Review of Hyperuricaemia and Hypertension: A Target for Treatment

Abstract

Hypertension is a significant cardiovascular risk factor with multifactorial aetiology. The link between hypertension and hyperuricaemia has been noted for over a century however determining whether this link is causal and whether there is a role for management of hyperuriaemia in the context of hypertension has been more problematic. Over the past two decades research in this area has dramatically increased with development of animal models of hyperuricaemia and use of large observational cohorts. There is an emerging body of evidence that hyperuricaemia should be considered an independent risk factor for the development of essential hypertension and that further research into the management of hyperuricaemia is required.

Ameliorative effect of cheqianzi decoction on hyperuricemia and kidney injury and underlying mechanism in rats

“…Furthermore, the degree of kidney injury in patients with HUA increases gradually with the SUA level [ 6 ]. At present, the drugs commonly used to treat HUA include xanthine oxidase inhibitor (allopurinol and Febuxostat) and UA reabsorption inhibitors (benzbromarone and probenecid) [ 7 , 8 ]. Although these drugs show good effects in reducing SUA, they do not significantly improve kidney injury associated with HUA [ 9 ], and can induce adverse reactions such hepatotoxicity, increased cardiovascular risk and severe drug eruption, and even death [ [10] , [11] , [12] ].…”